• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    C

    Centro Cardiologico Monzino,Istituti di Ricovero e Cura a Carattere Scientifico

    EST. 1981
    1,887论文总数
    4.6万引用总数

    论文量&引用量时间轴

    机构学者

    论文(1887)

    年份
    起
    –
    止
    排序
    1Stratified Treatment of Myocardial Infarction with Non-Obstructive Coronary Arteries: the PROMISE Trial.
    Rocco A Montone,Nicola Cosentino,Riccardo Gorla,Simone Biscaglia,Giulia La Vecchia,Riccardo Rinaldi,Andrea Caffè, Marta Resta,Andrea Erriquez,Francesco Bedogni,Giampaolo Niccoli,Carlo Trani,

    BACKGROUND AND AIMS:Myocardial infarction with non-obstructive coronary arteries (MINOCA) is associated with a significant risk of mortality, rehospitalization, and angina burden. Despite its clinical impact, no randomized clinical trials have hitherto evaluated optimal management strategy for MINOCA. The PROMISE trial was designed to assess whether a stratified treatment improves clinical outcomes in patients with MINOCA as compared to standard care. METHODS:PROMISE is a multicentre randomized trial. Patients with MINOCA were randomized 1:1 to either a stratified treatment based on a comprehensive diagnostic workup aimed at identifying the underlying aetiology, or to standard care. The primary endpoint was the between-group difference in the change in angina status at 12 months, assessed by the Seattle Angina Questionnaire summary score (SAQSS). The secondary endpoint was the incidence of major adverse cardiovascular events (MACE), defined as the composite of all-cause mortality, myocardial infarction, stroke, heart failure hospitalization and repeated coronary angiography. The trial was terminated early upon recommendation by the Data and Safety Monitoring Board due to clear benefits observed in the intervention group and potential harm in the control group. RESULTS:Of 101 randomized patients, 92 were confirmed as MINOCA and included in the final analysis (mean age 62 ± 13 years, 48% women; stratified treatment n = 45; standard care n = 47). At 12-month follow-up, SAQSS was significantly higher in the stratified treatment than in standard care group, with a mean between-group difference of +9.38 in favour of the stratified treatment (95% confidence interval 6.81 to 11.95; P < .001). MACE occurred in 1 patient (2.2%) in the stratified treatment and in 4 patients (8.5%) in the standard care group, though the difference was not statistically significant (P = .18). CONCLUSIONS:In this first randomized trial of treatment strategies in MINOCA, a stratified treatment, based on comprehensive diagnostic assessment and aetiology-guided therapy, led to a significant improvement in angina-related health status. While the study findings provide the first evidence supporting individualized management in this heterogeneous and often under-recognized patient population, these results require confirmation in a larger prospective study with longer follow-up.

    2026European heart journal(2026)引用:4
    引用
    AI阅读
    加入学术空间
    2Lysolecithin Reprogramming Via LPCAT1 Modulation Restores Endothelial Function and Prevents Diabetes-Associated Dysmetabolism
    Eduardo Maria Sommella,Concetta Iside, Paola Di Pietro,Fabrizio Merciai,Emanuela Salviati,Marina Sala, Angela Carmelita Abate,Antonio Damato,Massimiliano De Lucia,Eleonora Venturini, Valeria Prete, Francesca Picone,

    Dysregulation of lysophosphatidylcholines (LPCs) and phosphatidylcholines (PCs) is linked to endothelial dysfunction and impaired tissue repair. Nevertheless, the organ-specific modulation of lysolecithin remodeling in T2DM remains unexplored. Here, we investigate the LPC/PC remodeling dynamics in a T2DM model and propose a novel therapeutic approach using an orally bioavailable peptide (SP6) derived from Spirulina platensis. LPC/PC levels were analyzed by UHPLC-HRMS. Membrane fluidity, VEGF/API5, LPCAT1, VE-cadherin, and GLUT1 were evaluated by merocyanine assay, qPCR, immunoblotting, and immunofluorescence. In vivo, T2DM was induced by a high-fat diet and streptozotocin, and SP6 was orally administered. Tissue lipidomics, GLUTs expression, and insulin secretion were assessed, with the latter also spatially characterized in pancreatic tissue by MALDI-MS imaging. High glucose induced LPC/PC imbalance, enhanced membrane fluidity, impaired VEGF/API5 expression, and hindered wound healing and VE-cadherin localization via LPCAT1 downregulation and subsequent impact on GLUT1 translocation. In vivo analysis of diabetic mice revealed a multi-organ influence of SP6 preserving LPCAT1 mRNA levels in pancreas, liver, skeletal muscle, and adipose tissue and a specific pattern of lysolecithin remodeling, with selective modulation of LPC 16:0, 18:0, and 20:4 in plasma. Finally, its effects in T2DM are mediated by preserving insulin secretion and glycemic control through increased ATP production. These findings reveal tissue-specific lysolecithin reprogramming in T2DM development and identify LPCAT1-mediated lysolecithin remodeling as a mechanism involved in T2DM-related endothelial and metabolic dysfunction. SP6 modulates lipid metabolism, vascular integrity, and glucose regulation at the transcript level, suggesting its potential as a new preventive treatment for T2DM and its complications.

    2026Cardiovascular Diabetology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Transcatheter Tricuspid Valve Replacement in Patients with Cardiac Implantable Electronic Device Leads: the TRIPLACE Registry
    Bryan P Traynor,Andrea Scotti,Rishi Puri,Matteo Sturla,Firas Zahr,Robert Boone,Susheel Kodali,Didier Tchétché,Ole De Backer,Augustin Coisne,Sebastian Ludwig,Lukas Stolz,

    BACKGROUND:Patients undergoing orthotopic transcatheter tricuspid valve replacement (TTVR) frequently present with a cardiac implantable electronic device (CIED) lead traversing the tricuspid valve. OBJECTIVES:This study sought to investigate the clinical, procedural, and lead-related outcomes of orthotopic TTVR in patients with transvalvular CIED leads. METHODS:All consecutive patients enrolled in the multicenter TRIPLACE (Global Multicenter Registry on Transcatheter Tricuspid Valve Replacement) registry were included for analysis. Patients were stratified based on the presence of a CIED lead traversing the tricuspid valve. Changes in lead function parameters were assessed after TTVR in a subset of these patients who had pacemaker lead parameter data recorded. Lead failure was defined as structural or electrical malfunction requiring new lead or CIED insertion. RESULTS:Among 395 patients, 104 (26.3%) had transvalvular CIED leads. Procedural success, symptomatic improvement, and 30-day mortality were comparable between those with and without CIED. Patients with CIED leads had lower rates of mild or less residual tricuspid regurgitation (82.6% vs 91.4%; P < 0.041) and higher rates of moderate or greater paravalvular leak (17.1% vs 7.1%; P < 0.017). Lead failure occurred in 5.8% over a median follow-up time of 183 days, with modest changes in pacing thresholds. No significant increase in adverse events or mortality was observed at 30 days. CONCLUSIONS:Orthotopic TTVR in patients with transvalvular CIED leads can be safely and effectively performed with low rates of lead failure. Significant paravalvular leak and residual tricuspid regurgitation is more common with a jailed lead. These patients require close CIED follow-up with alternative pacing strategies in place, particularly when pacing dependent. (Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment [TRIPLACE]; NCT06033274).

    2026JACC Clinical electrophysiology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Whole Blood Flow Cytometric Quantification of Tissue Factor-Positive Platelets: A Harmonized Multicenter Workflow.
    Marta Brambilla,Alessia Becchetti,Kevin Nallio,Arianna Galotta,Manuela Capone,Martina Toma,Roberto Caporale,Antonella Aiello,Marina Camera

    Tissue Factor (TF)pos-platelets represent a subset of the platelet population. Recently, this subset has been shown to predict cardiovascular mortality in patients with coronary artery disease, establishing it as a biomarker useful for thrombotic risk stratification. Accurate quantification of TFpos-platelets by flow cytometry requires strict standardization of pre-analytical handling, staining procedures, and instrument settings, particularly in multicenter studies where technical variability may affect their measurement. This protocol describes a harmonized workflow for whole-blood flow cytometry assessment of circulating TFpos-platelets, designed to ensure reproducibility across laboratories with different technical infrastructures. The procedure includes standardized blood collection and whole-blood fixation to preserve the in vivo platelet phenotype. Two different methods for sample preparation are provided according to local laboratory capabilities: shipment of fixed samples to the Core Laboratory for centralized staining, acquisition, and analysis for centers without flow cytometry facilities, or local staining and acquisition for centers equipped with flow cytometry instrumentation and trained personnel. The assessment of the percentage of TFpos-platelets is achieved by direct labeling with anti-TF Star Fluor 488 and anti-CD41 PerCP-Cy5.5 antibodies to identify the target protein and the platelet population marker, respectively. Flow cytometer harmonization is achieved either through a shared acquisition template for identical cytometer models or through bead-based alignment for different platforms. The workflow further incorporates a standardized gating approach and centralized data analysis to enable reliable comparison of TFpos-platelet measurements across sites. Representative results demonstrated that this workflow supports reproducible quantification of TFpos-platelets across the validated multicenter acquisition settings. This protocol may facilitate broader application of TFpos-platelet assessment in thrombotic risk stratification and support wider standardization of platelet flow cytometry in translational and clinical research.

    2026Journal of visualized experiments JoVE(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Dyspnea and Fatigue in Long-COVID: Definition of Risk Factors and of DLCO-based Phenotypes in a Multicenter Study of 765 Patients from Italy.
    Marco Floridia,Liliana Elena Weimer,Aldo Lo Forte,Paolo Palange,Piergiuseppe Agostoni,Maria Rosa Ciardi,Matteo Tosato,Donato Lacedonia,Paola Gnerre,Emanuela Barisione, Giuseppe Pio Martino,Guido Vagheggini,

    BACKGROUND:Dyspnea and fatigue represent common Long-COVID symptoms, but their presence is not always accompanied by lung function abnormalities. Aim of the study was to evaluate dyspnea and fatigue in relation to pulmonary function and exercise capacity. METHODS:Multicenter cohort study. Multivariable analyses were used to characterize, for both symptoms, functional phenotypes with and without pulmonary impairment according to the diffusing lung capacity for carbon monoxide (DLCO). Exercise capacity was assessed through the distance walked in 6 min (6MWD). RESULTS:Among 765 patients evaluated at a mean interval of six months from COVID-19, rates of dyspnea and fatigue were 41.3% and 41.6%, respectively. Roughly half of the patients with these two symptoms (51.6% and 54.7%, respectively) had normal pulmonary function at DLCO testing (≥80% of predicted). Low-DLCO (<80%) dyspnea was significantly associated with female sex, anxiety, duration of hospitalisation, use of corticosteroids and of monoclonal neutralizing antibodies, and its risk decreased at the increasing in time from acute infection. Normal-DLCO dyspnea was associated with younger age and obesity. Low-DLCO fatigue was associated with female sex, heart failure, anxiety and use of corticosteroids. Normal-DLCO fatigue was not associated with demographics, comorbidities, or COVID-19 severity. For both symptoms, the low-DLCO phenotypes had a significantly lower 6MWD. CONCLUSIONS:The clinical phenotypes of dyspnea and fatigue with normal pulmonary function should be further explored, possibly with additional tests that assess cardiorespiratory and cardiovascular function. DLCO testing should be included in the evaluation of patients who report dyspnea and/or fatigue as possible Long-COVID symptoms.

    2026Respiratory medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1887 篇论文

    合作机构(100)

    米兰大学合作论文 407
    意大利科学领域恢复与治疗研究所合作论文 167
    IRCCS Policlinico San Donato,Istituti di Ricovero e Cura a Carattere Scientifico合作论文 77
    罗马大学合作论文 69
    那不勒斯费德里克二世大学合作论文 66
    帕多瓦大学合作论文 66
    圣心天主教大学合作论文 44
    米兰比可卡大学合作论文 36
    维罗纳大学合作论文 33
    卡塔尼亚大学合作论文 33

    机构统计